What is Roth Capital’s Estimate for CYCC Q1 Earnings?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Stock analysts at Roth Capital issued their Q1 2025 earnings per share estimates for Cyclacel Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff expects that the biotechnology company will post earnings per share of ($0.29) for the quarter. Roth Capital has a “Hold” rating on the stock. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($2.29) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million.

Separately, StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research report on Friday. They issued a “sell” rating on the stock.

Cyclacel Pharmaceuticals Stock Performance

CYCC opened at $0.37 on Thursday. The company has a fifty day moving average price of $0.85 and a two-hundred day moving average price of $1.42. The firm has a market capitalization of $804,100.00, a PE ratio of -0.04 and a beta of 0.56. Cyclacel Pharmaceuticals has a 52 week low of $0.35 and a 52 week high of $6.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC bought a new position in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.